VRPX.OTC.PinkVirpax Pharmaceuticals, INC
S-1/A: Virpax Pharmaceuticals Seeks $7 Million in Best Efforts Offering to Advance Pain Management Pipeline
Sentiment:
Prospectus
Virpax Pharmaceuticals launches a best efforts offering of common stock and pre-funded warrants to raise up to $7 million for clinical trials and corporate purposes.
Capital raiseThe company is offering up to 6,422,018 shares of common stock and pre-funded warrants in a best efforts offering.The company aims to raise approximately $7 million, assuming a public offering price of $1.09 per share.The company recently completed a public offering in May 2024, raising approximately $2.25 million.The company recently completed a private placement in July 2024, raising $2.5 million, which was used to pay the remaining settlement with Sorrento and Scilex.
Worse than expectedThe company's stockholders' deficit and low cash position are worse than expected, raising concerns about its ability to continue as a going concern.
Summary
- Virpax Pharmaceuticals is undertaking a best efforts public offering to sell up to 6,422,018 shares of common stock and pre-funded warrants.
- The company aims to raise approximately $7 million, assuming a public offering price of $1.09 per share.
- The offering includes pre-funded warrants for investors who would exceed beneficial ownership limits with direct stock purchases.
- Net proceeds will primarily fund clinical trials for Probudur and for general corporate purposes.
- The offering is set to terminate on September 15, 2024, unless fully subscribed or terminated earlier.
- The company is currently not compliant with Nasdaq's minimum stockholders' equity requirement and has been granted an extension until September 30, 2024 to regain compliance.
- The company recently settled litigation with Sorrento and Scilex for $6 million and ongoing royalties.
- The company recently completed a public offering in May 2024, raising approximately $2.25 million.
- The company recently completed a private placement in July 2024, raising $2.5 million, which was used to pay the remaining settlement with Sorrento and Scilex.
Sentiment
Score: 4
Explanation: The document presents a mixed sentiment. While there are positive developments such as positive study results and settlement of litigation, the company's financial challenges and Nasdaq compliance issues weigh negatively.
Positives
- The offering aims to fund clinical trials for Probudur, a key product candidate.
- The company has secured an extension to regain compliance with Nasdaq's minimum stockholders' equity requirement.
- The company recently announced positive results for a Swine Model pilot study for Probudur, our long-acting liposomal bupivacaine formulation.
- The company has settled litigation with Sorrento and Scilex, removing a significant legal overhang.
Negatives
- The company is not currently compliant with Nasdaq's minimum stockholders' equity requirement.
- The company has a history of operating losses and requires additional capital to fund operations.
- The company's cash position is low, with approximately $0.9 million as of August 6, 2024.
- The company's recent settlement with Sorrento and Scilex for $6 million and ongoing royalties has negatively impacted its cash position.
- The company's management has broad discretion in using the net proceeds from this offering.
Risks
- Failure to raise sufficient capital in this offering could force the company to delay or eliminate research and development programs.
- The company may not be able to comply with Nasdaq's minimum stockholders' equity requirement, potentially leading to delisting.
- The company's reliance on preclinical stage product candidates carries significant development and regulatory risks.
- The company's dependence on third parties for manufacturing and clinical trials poses operational risks.
- The company's lack of a sales and marketing organization presents challenges for commercializing product candidates.
- The company's management has broad discretion in using the net proceeds from this offering.
- The company's former Chief Executive Officer, Mr. Mack, may seek indemnification and/or damages from us and if he were successful in his claim, we may determine to use a portion of the proceeds from this offering to make such payments.
Future Outlook
The company anticipates commencing clinical trials for Probudur in first quarter of 2025 and Envelta in first half of 2025, but there can be no assurances that the trials will commence on the anticipated timeline presented, or at all.
Industry Context
The announcement reflects the ongoing capital-raising activities common among preclinical-stage pharmaceutical companies to fund research and development.
Comparison to Industry Standards
- Comparable companies in the preclinical stage often rely on equity financing to advance their drug candidates.
- The best efforts nature of the offering is typical for smaller companies with limited operating history.
- The use of proceeds for clinical trials and general corporate purposes aligns with industry norms for companies in this stage of development.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Barbara Ruskin | Judy Su | July 5, 2024 | Resignation and appointment |
| Director | Jerrold Sendrow | Jatinder Dhaliwal | July 5, 2024 | Resignation and appointment |
| Director | Jeffrey Gudin | Katharyn Field | July 5, 2024 | Resignation and appointment |
| Director | Thani Jambulingam | Gary Herman | July 5, 2024 | Resignation and appointment |
| Director | Michael F. Dubin | July 5, 2024 | Resignation |
Legal Proceedings
- The company recently settled litigation with Sorrento and Scilex for $6 million and ongoing royalties.
Stakeholder Impact
- Shareholders face potential dilution from the offering.
- Employees may benefit from the company's ability to fund ongoing development activities.
- Customers may benefit from the potential commercialization of new pain management treatments.
Next Steps
- Complete the public offering by September 15, 2024.
- Commence clinical trials for Probudur in the first quarter of 2025.
- Commence clinical trials for Envelta in the first half of 2025.
- Regain compliance with Nasdaq's minimum stockholders' equity requirement by September 30, 2024.
Key Dates
| Date | Description |
|---|---|
| February 29, 2024 | Filed a certificate of amendment to our Amended and Restated Certificate of Incorporation for purposes of effecting a 1-for-10 reverse stock split |
| February 29, 2024 | Entered into a Settlement Agreement and Mutual Release with Sorrento Therapeutics, Inc. (Sorrento), and Scilex Pharmaceuticals Inc. |
| March 1, 2024 | The Plaintiffs filed a motion to approve the Settlement Agreement and grant the related relief with the Bankruptcy Court. |
| March 1, 2024 | Reverse Split of our outstanding shares of Common Stock such that, effective upon March 1, 2024, the day after the filing thereof, every 10 issued and outstanding shares of our Common Stock were subdivided and reclassified into one validly issued, fully paid and non-assessable share of our Common Stock. |
| March 14, 2024 | The Bankruptcy Court entered an order approving the Settlement Agreement |
| March 18, 2024 | Initial payment of $3.5 million was paid two business days after the date that the Settlement Order was entered by the Bankruptcy Court |
| March 20, 2024 | The Plaintiffs filed a Stipulation of Dismissal with the Chancery Court of the State of Delaware (the Chancery Court) dismissing the Action. |
| April 2, 2024 | Received a notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (Nasdaq) notifying us that our stockholders equity as reported in our Annual Report on Form 10-K for the period ended December 31, 2023 (the Annual Report), did not meet the minimum stockholders equity requirement for continued listing on the Nasdaq Capital Market. |
| May 17, 2024 | Consummated a public offering (the Public Offering) |
| June 28, 2024 | Received written notice from the Listing Qualifications Department of Nasdaq notifying us that for the preceding 30 consecutive business days (May 15, 2024 through June 27, 2024), the Companys Common Stock did not maintain a minimum closing bid price of $1.00 (Minimum Bid Price Rule) per share as required by Nasdaq Listing Rule 5550(a)(2). |
| June 30, 2024 | Reported stockholders deficit of $2,794,498 in our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024. |
| July 5, 2024 | Entered into a Securities Purchase Agreement (the Purchase Agreement), with an institutional investor (the Investor) pursuant to which, on July 5, 2024, we issued to the Investor a senior secured promissory note in the principal amount of $2.5 million (the Secured Note) for $2.5 million (the Subscription Amount). |
| July 8, 2024 | The remaining $2.5 million was paid on July 8, 2024 to Sorrento and Scilex. |
| July 8, 2024 to July 19, 2024 | The staff has determined that for 10 consecutive business days, from July 8, 2024 to July 19, 2024, the closing bid price of the Companys Common Stock had been at $1.00 per share or greater. |
| July 10, 2024 | Issued a press release announcing positive results for a Swine Model pilot study for Probudur, our long-acting liposomal bupivacaine formulation. |
| July 22, 2024 | Received a notice from the Listing Qualifications Department of Nasdaq notifying the Company that the staff has determined that for 10 consecutive business days, from July 8, 2024 to July 19, 2024, the closing bid price of the Companys Common Stock had been at $1.00 per share or greater. |
| July 25, 2024 | Used approximately $2.5 million of the proceeds received from the exercise of the Common Warrants issued in the Public Offering to repay the Secured Note in full, including principal and interest. |
| July 29, 2024 | Received notice from the Listing Qualifications Staff (the Staff) of The Nasdaq that we were granted an extension through September 30, 2024 to regain compliance with Nasdaq Listing Rule 5550(b)(1). |
| September 15, 2024 | This offering will terminate on September 15, 2024, unless the offering is fully subscribed before that date, or we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. |
| September 30, 2024 | Granted an extension through September 30, 2024 to regain compliance with Nasdaq Listing Rule 5550(b)(1). |
| December 26, 2024 | Given a compliance period of 180 calendar days, or until December 26, 2024, to regain compliance with Nasdaq Listing Rule 5550(a)(2). |
Keywords
public offering, pre-funded warrants, common stock, clinical trials, Virpax Pharmaceuticals, capital raise, Probudur, Nasdaq compliance, settlement, biopharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.